Moneycontrol PRO

Buy Ajanta Pharmaceuticals; target of Rs 1955: ICICI Direct

ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1955 in its research report dated May 11, 2022.

May 12, 2022 / 04:06 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Ajanta Pharmaceuticals

Ajanta Pharma is a focused player in branded, which constitutes ~72% of overall sales, spread across geographies including India. As of FY22, overall exports: domestic formulations ratio was at 70:30 • Among exports, Asia accounts for ~35% of export formulations, Africa 34% & US 30%. The company also participates in anti-malarial tenders in Africa (included in Africa).


We maintain BUY as it remains a compelling play on branded generics (~72% exposure) with strong execution track record and financials. Valued at Rs 1955 i.e. 20x P/E on FY24E EPS of Rs 97.8.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 12, 2022 04:06 pm
ISO 27001 - BSI Assurance Mark